Publications by authors named "Chardain A"
Importance: Risk factors associated with the severity of coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (MS) are unknown. Disease-modifying therapies (DMTs) may modify the risk of developing a severe COVID-19 infection, beside identified risk factors such as age and comorbidities.
Objective: To describe the clinical characteristics and outcomes in patients with MS and COVID-19 and identify factors associated with COVID-19 severity.
Posterior reversible encephalopathy syndrome (PRES) is a serious neurological condition encountered in various medical fields. Pathophysiological factor(s) common to PRES cases of apparently unrelated etiologies are yet to be found. Based on the hypothesis that hypomagnesemia might participate in the cascade leading to PRES, our study sought to verify whether hypomagnesemia is frequently associated with PRES regardless of etiology.
View Article and Find Full Text PDFBackground: Quantitative in vivo imaging of myelin loss and repair in patients with multiple sclerosis (MS) is essential to understand the pathogenesis of the disease and to evaluate promyelinating therapies. Selectively binding myelin in the central nervous system white matter, Pittsburgh compound B ([ C]PiB) can be used as a positron emission tomography (PET) tracer to explore myelin dynamics in MS.
Methods: Patients with active relapsing-remitting MS (n = 20) and healthy controls (n = 8) were included in a longitudinal trial combining PET with [ C]PiB and magnetic resonance imaging.
Progressive multifocal leukoencephalopathy (PML) is the main adverse effect of natalizumab. Detectable JC virus-specific effector memory T-cell (TEM) responses may indicate ongoing JCV replication. We detected JCV-specific TEM responses in blood of patients with multiple sclerosis (MS) treated with natalizumab, including 2 patients with PML.
View Article and Find Full Text PDFArticle Synopsis
- Imaging myelin tracts in vivo can enhance the understanding and monitoring of demyelinating diseases like multiple sclerosis (MS), as traditional techniques do not target these processes specifically.
- A new study examined the potential of the amyloid marker PIB, which binds to CNS myelin, to serve as a myelin marker through fluorescence studies and PET imaging in both animal models and MS patients.
- Results showed PIB effectively stained myelin and distinguished between demyelinated and remyelinated areas, indicating its usefulness for quantifying myelin loss and repair in demyelinating diseases.